Engineered Exosomes for Targeted Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering immunomodulatory molecules to treat cancer, graft-versus-host disease (GvHD), and autoimmune diseases are inadequate, lacking effective and targeted approaches to modulate the human immune system.
Innovation Solution
Compositions comprising extracellular vesicles engineered with immunomodulating components, such as inhibitors or activators of checkpoint regulators, co-stimulatory molecules, cytokines, and tumor antigens, to up-regulate or down-regulate the immune response, enhancing immune therapy for cancer treatment and alleviating symptoms of GvHD and autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional drug delivery methods are used to deliver immunomodulatory molecules, then the molecules can be delivered to cells and tissues, but the delivery is not effective or targeted enough to modulate the immune system efficiently
Solution Approach 1:
Extracellular vesicles serve as intermediary carriers to deliver immunomodulatory molecules (such as checkpoint inhibitors, co-stimulatory molecules, cytokines, and tumor antigens) to target cells and tissues. These vesicles naturally interact with immune cells and can cross biological barriers, thereby enhancing the reliability of immune system modulation while maintaining relative simplicity in the delivery approach
Solution Approach 2:
The patent modifies the properties of extracellular vesicles by selecting, enriching, or engineering them with specific immunomodulating components. This changes the functional parameters of the vesicles to optimize their ability to activate, suppress, or influence the human immune system, thereby improving therapeutic effectiveness
2Reliability
If extracellular vesicles are engineered with multiple immunomodulating components to enhance immune therapy, then treatment outcomes improve, but the complexity of composition and production increases
Solution Approach 1:
The extracellular vesicles are engineered to perform multiple functions simultaneously by incorporating different types of immunomodulating components (checkpoint inhibitors, co-stimulatory molecules, cytokines, tumor antigens). This multi-functionality allows a single vesicle composition to address multiple aspects of immune modulation, improving treatment outcomes while managing complexity through a unified delivery platform
Solution Approach 2:
The patent divides the immunomodulatory therapy into discrete functional components that can be independently selected and enriched in the extracellular vesicles. This segmentation allows for modular design where specific components can be tailored to treat different conditions (cancer, GvHD, autoimmune diseases) without redesigning the entire system
3Measurement precision
If extracellular vesicles are used to deliver immunomodulatory molecules, then targeted delivery to immune cells is achieved, but the manufacturing and isolation processes become more difficult
Solution Approach 1:
The extracellular vesicles naturally possess surface markers and properties that enable them to self-target specific immune cells without requiring extensive external modification. This self-service capability allows the vesicles to autonomously navigate to and interact with their target cells, maintaining targeting accuracy while simplifying the manufacturing process by reducing the need for complex conjugation or modification steps
Data Source
AI summary
Disclosed herein are extracellular vesicles comprising an immunomodulating component. Also provided are methods for producing the extracellular vesicles and methods for using the extracellular vesicles for treating cancer, GvHD, and autoimmune diseases.